BIOPHARMA
ByCan Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience Into 2026?
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Can Novartis’ 2025 Approvals and Launches Strengthen Its Position Across Oncology, Neuroscience, and Rare Diseases Into 2026?
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology, Immunology, and MedTech Into 2026 and Beyond?
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver Disease Into 2026 and Beyond?
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…
Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66 Million NLRP3 Licensing Deal
23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…
